1. |
Nanda A, Chen M, Renshaw A, et al. Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009; 74: 1419-23.
|
2. |
McGuire BB, Helfand BT, Loeb S, et al. Outcomes in patients with Gleason score 8-10 prostate cancer: Relation to preoperative PSA level. BJU Int 2012; 109: 1764-9.
|
3. |
Krauss DJ, Hayek S, Amin M, et al. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81:119-25.
|
4. |
Serni S, Masieri L, Minervini A, et al. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology 2006; 67:373-8.
|
5. |
Stock R, Cesaretti J, Hall S, et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009; 104:1631-6.
|
6. |
Ellis CL, Partin AW, Han M, et al. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: Correlation with findings at radical prostatectomy and prognosis. J Urol 2013; 190:2068-73.
|
7. |
Humphrey PA. Gleason pattern 5 adenocarcinoma in prostate needle biopsy. J Urol 2012; 188:1341-2.
|
8. |
Consensus Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035-41.
|
9. |
Sabolch A, Feng F, Daignault-Newton S, et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011; 81:351-60.
|
10 |
D'Ambrosio DJ, Hanlon AL, Al-Saleem T, et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67:1082-7.
|
11 |
Lughezzani G, Gallina A, Larcher A, et al. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int 2013; 111: 723-30.
|
12 |
Pahlajani N, Ruth KJ, Buyyounouski MK, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Int J Radiat Oncol Biol Phys 2012; 82:1949-56.
|
13 |
D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs . radiation alone for prostate cancer: A randomized trial. JAMA 2008; 299:289-95.
|
14 |
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase Ⅲ RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285-90.
|
15 |
Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: Predictors of long- term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011; 60: 1133-9.
|
16 |
Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 11:2516-27.
|
17 |
Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000; 163:1739-42.
|
18 |
Inman BA, DiMarco DS, Slezak JM, et al. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology 2006; 68:604-8.
|